Pfizer: Vaccine Is 100 Percent Effective In Adolescents

Pfizer and BioNTech’s COVID-19 vaccine was 100 percent effective in protecting adolescents between the ages of 12 and 15, the companies announced Monday.

The results of a long-term trial of 2,228 youth, measured from seven days to more than four months after the second dose, will form the basis for a planned additional application to the Food and Drug Administration (FDA) to expand the vaccine’s approval. expand. for use in individuals in that age group, the companies said.

The data was collected from November 2020 to September 2021, when the delta variant began to infect large segments of the US population.

The vaccine is available for emergency use individuals ages 12 to 15, which was issued in May.

“As the global health community works to increase the number of people vaccinated around the world, these additional data provide greater confidence in the safety and effectiveness profile of our vaccine in adolescents,” Pfizer CEO Albert Bourla said in a statement.

Efficacy was consistently high for gender, race and ethnicity, obesity and comorbidity demographics, the companies said.

In addition, there were no serious safety concerns during a follow-up period of at least six months after the second dose of the vaccine.

There were 30 symptomatic infections in the study, all in the placebo arm.

“These are the first and only longer-term publicly available data demonstrating the safety and efficacy of a COVID-19 vaccine in individuals ages 12 to 15,” said Ugur Sahin, BioNTech’s CEO and co-founder. The amount of data we have collected to date from clinical trials and real-world surveillance strengthens the evidence base supporting the strong efficacy and favorable safety profile of our COVID-19 vaccine in adolescent and adult populations.


Leave a Comment